| | Δmm swelling | Uterus weight (mg) |
|---|
Vehicle po | 1.2 ± 0.4 | 19.9 ± 7.0 |
Dexamethasone | | |
3 mg/kg po | 0.0 ± 0.0* | 29.7 ± 17.4 |
EE 0.025 mg/kg po | 0.7 ± 0.4 | 109.5 ± 23.8* |
EE 0.25 mg/kg po | 0.4 ± 0.2* | 91.1 ± 14.4* |
EE 2.5 mg/kg po | 0.6 ± 0.3* | 84.8 ± 17.1* |
Vehicle po | 1.1 ± 0.4 | 11.1 ± 1.6 |
Dexamethasone | | |
3 mg/kg po | 0.0 ± 0.0* | 14.7 ± 3.5 |
ERA-63 1.5 mg/kg po | 0.7 ± 0.3* | 136.6 ± 19.9* |
ERA-63 3 mg/kg po | 0.5 ± 0.2* | 113.6 ± 15.4* |
ERA-63 6 mg/kg po | 0.4 ± 0.2* | 92.1 ± 14.5* |
Vehicle sc | 1.3 ± 0.1 | 13.4 ± 0.8 |
EE 0.25 mg/kg sc | 0.5 ± 0.1* | 148.8 ± 6.4* |
ERB-79 3 mg/kg sc | 1.1 ± 0.2 | 14.8 ± 1.8 |
- Mice (n = 8 per group) were ovariectomized at day -14. Animals were treated daily for 10 days (day -1 to day 9) with ethinyl estradiol (EE) (0.025, 0.25 and 2.5 mg/kg), ERA-63 (1.5, 3 and 6 mg/kg), the positive control dexamethasone (3 mg/kg) or vehicle (0.5% gelatin and 5% mannitol in water). ERB-79 was dosed subcutaneously at 3 mg/kg per day (2 × 1.5 mg/kg). Animals were immunized at day 0 and boosted at day 7. Twenty four hours after challenge the footpad swelling was measured. Forty eight hours after challenge mice were euthanized and the uterus was dissected and weighed. Statistical analysis was performed with analysis of variance. * P < 0.05. DTH, delayed type hypersensitivity; ER, estrogen receptor; po, orally; sc, subcutaneous.
